This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

RxStrategies' antitrust claims against CVS allowed to move forward

( December 4, 2019, 22:31 GMT | Official Statement) -- MLex Summary: US District Judge James S. Moody has denied CVS’s motion to dismiss claims accusing it of unlawfully tying its contract pharmacy services to its software and technology solutions for pharmacies and hospitals participating in the 340B Drug Pricing Program in order to keep out competition. Moody concluded that RxStrategies has sufficiently alleged CVS’s market power for the defined geographic market to withstand a motion to dismiss.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections